Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.520
-0.300 (-7.85%)
At close: Mar 13, 2025, 4:00 PM
3.512
-0.009 (-0.24%)
After-hours: Mar 13, 2025, 7:56 PM EST
Iovance Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 164.07 | 1.19 | - | - | - | |
| Revenue Growth (YoY) | 13698.99% | - | - | - | - | |
| Cost of Revenue | 124 | 10.76 | - | - | - | |
| Gross Profit | 40.08 | -9.57 | - | - | - | |
| Selling, General & Admin | 153.02 | 106.92 | 104.1 | 83.66 | 60.21 | |
| Research & Development | 282.34 | 344.08 | 294.78 | 259.04 | 201.73 | |
| Operating Expenses | 435.35 | 450.99 | 398.88 | 342.7 | 261.94 | |
| Operating Income | -395.28 | -460.56 | -398.88 | -342.7 | -261.94 | |
| Interest & Investment Income | 10.01 | 9.44 | 3.46 | 6.46 | 4.22 | |
| EBT Excluding Unusual Items | -385.27 | -451.12 | -395.42 | -336.24 | -257.72 | |
| Gain (Loss) on Sale of Investments | 10.26 | 3.61 | -0.47 | -6.01 | -1.87 | |
| Pretax Income | -375.01 | -447.52 | -395.89 | -342.25 | -259.58 | |
| Income Tax Expense | -2.83 | -3.48 | - | - | - | |
| Net Income | -372.18 | -444.04 | -395.89 | -342.25 | -259.58 | |
| Net Income to Common | -372.18 | -444.04 | -395.89 | -342.25 | -259.58 | |
| Shares Outstanding (Basic) | 290 | 235 | 159 | 153 | 138 | |
| Shares Outstanding (Diluted) | 290 | 235 | 159 | 153 | 138 | |
| Shares Change (YoY) | 23.28% | 47.64% | 3.82% | 10.92% | 11.23% | |
| EPS (Basic) | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | |
| EPS (Diluted) | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | |
| Free Cash Flow | -364.05 | -384.11 | -313.18 | -265.52 | -251.93 | |
| Free Cash Flow Per Share | -1.26 | -1.63 | -1.97 | -1.73 | -1.82 | |
| Gross Margin | 24.43% | - | - | - | - | |
| Operating Margin | -240.92% | -38734.99% | - | - | - | |
| Profit Margin | -226.84% | -37345.42% | - | - | - | |
| Free Cash Flow Margin | -221.88% | -32305.30% | - | - | - | |
| EBITDA | -362.11 | -439.14 | -389.57 | -339.59 | -260.8 | |
| EBITDA Margin | -220.70% | - | - | - | - | |
| D&A For EBITDA | 33.17 | 21.42 | 9.31 | 3.11 | 1.14 | |
| EBIT | -395.28 | -460.56 | -398.88 | -342.7 | -261.94 | |
| EBIT Margin | -240.92% | - | - | - | - | |
| Revenue as Reported | 164.07 | 1.19 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.